Ribavirin Powder, For Solution
NDC Package 68682-019-01
Package Information
Ribavirin powders is ribavirin is used in combination with other antiviral medications (such as interferon, sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. This formulation utilizes a powder, for solution delivery system. Marketed by Oceanside Pharmaceuticals, this product is identified by NDC 68682-019 and is authorized under FDA application NDA018859.
Identification & Billing
- RxCUI: 312818 - ribavirin 6 GM Inhalation Solution
- RxCUI: 312818 - ribavirin 20 MG/ML Inhalation Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68682 - Oceanside Pharmaceuticals
- 68682-019 - Ribavirin
- 68682-019-01 - 1 VIAL, GLASS in 1 CARTON / 1 POWDER, FOR SOLUTION in 1 VIAL, GLASS
- 68682-019 - Ribavirin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (68682-019). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68682-019-01 identifies a specific commercial package of 1 vial, glass in 1 carton / 1 powder, for solution in 1 vial, glass of Ribavirin, a human prescription drug labeled by Oceanside Pharmaceuticals. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This powder, for solution is formulated for respiratory (inhalation) use and contains ribavirin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Oceanside Pharmaceuticals on April 14, 2017. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Ribavirin is used in combination with other antiviral medications (such as interferon, sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer. Ribavirin works by reducing the amount of hepatitis C virus in your body, which may help your liver recover. It is not known if this treatment can prevent you from passing the virus to others. Do not share needles, and practice "safer sex" (including the use of latex condoms) to lower the risk of passing the virus to others.
How is this Oceanside Pharmaceuticals product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68682001901. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.